2,3-(N-steroylsphingosyl)-1-phosphocholine: RN & structure given in first source; RN not in Chemline 12/87 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
N-stearoylsphingosine-1-phosphocholine : A sphingomyelin d18:1 in which the ceramide N-acyl group is specified as stearoyl (octadecanoyl). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
sphingomyelin 18:0 : A sphingomyelin in which the total number of carbons in the sphingoid base and fatty acyl groups is 18 with 0 double bonds. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
ID Source | ID |
---|---|
PubMed CID | 6453725 |
CHEMBL ID | 1609656 |
CHEBI ID | 83358 |
SCHEMBL ID | 14889266 |
MeSH ID | M0103076 |
Synonym |
---|
LMSP03010001 |
n-(octadecanoyl)-sphing-4-enine-1-phosphocholine |
c18 sphingomyelin |
sm(d18:1/18:0) |
NCGC00161363-01 |
2,3-sppc |
n-stearoyl-d-erythro-sphingosylphosphorylcholine |
58909-84-5 |
BML3-D05 |
[(e,2s,3r)-3-hydroxy-2-(octadecanoylamino)octadec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate |
sphingomyelin 18:0 |
05ug6280ni , |
3,5-dioxa-8-aza-4-phosphahexacosan-1-aminium, 4-hydroxy-7-(1-hydroxy-2-hexadecenyl)-n,n,n-trimethyl-9-oxo-, hydroxide, inner salt, 4-oxide, (r-(r*,s*-(e)))- |
stearoylsphingomyelin |
n-stearoylsphingosine-phosphorylcholine |
2,3-(n-steroylsphingosyl)-1-phosphocholine |
unii-05ug6280ni |
3,5-dioxa-8-aza-4-phosphahexacosan-1-aminium, 4-hydroxy-7-((1r,2e)-1-hydroxy-2-hexadecenyl)-n,n,n-trimethyl-9-oxo-, inner salt, 4-oxide, (7s)- |
n-stearoylsphingomyelin |
sphingomyelins n-stearoylsphingomyelin [mi] |
n-stearoylsphingosine-1-phosphocholine |
3,5-dioxa-8-aza-4-phosphahexacosan-1-aminium, 4-hydroxy-7-(1-hydroxy-2-hexadecenyl)-n,n,n-trimethyl-9-oxo-, inner salt, 4-oxide, (r-(r*,s*-(e)))- |
n-octadecanoylsphing-4-enine-1-phosphocholine |
stearoyl sphingomyelin |
(2s,3r,4e)-3-hydroxy-2-(octadecanoylamino)octadec-4-en-1-yl 2-(trimethylazaniumyl)ethyl phosphate |
n-stearoylsphing-4-enine-1-phosphocholine |
sphingomyelin (d18:1/18:0) |
(2s,3r,4e)-3-hydroxy-2-(stearoylamino)octadec-4-en-1-yl 2-(trimethylammonio)ethyl phosphate |
CHEBI:83358 , |
n-octadecanoylsphingosine-1-phosphocholine |
SCHEMBL14889266 |
CHEMBL1609656 |
AS-60769 |
(2-{[(2s,3r,4e)-3-hydroxy-2-octadecanamidooctadec-4-en-1-yl phosphonato]oxy}ethyl)trimethylazanium |
sm d36:1 |
18:0 sm (d18:1/18:0), n-stearoyl-d-erythro-sphingosylphosphorylcholine, powder |
brain sm, sphingomyelin (brain, porcine), powder |
ethanaminium, 2-[[hydroxy[[(2r,3s,4e)-3-hydroxy-2-[(1-oxooctadecyl)amino]-4-octadecen-1-yl]oxy]phosphinyl]oxy]-n,n,n-trimethyl-, inner salt, rel- |
134731-80-9 |
Q27156784 |
sphingomyelin from bovine brain |
n-octadecanoylsphingosylphosphorylcholine |
n-acyl-4-sphingenyl-1-o-phosphorylcholine;n-acyl-d-sphingosine-1-phosphocholine |
AKOS037645436 |
CS-0621186 |
HY-148388 |
DTXSID501313528 |
sphingomyelin (bovine spinal cord) |
ethanaminium,2-[[hydroxy[[(2r,3s,4e)-3-hydroxy-2-[(1-oxooctadecyl)amino]-4-octadecen-1-yl]oxy]phosphinyl]oxy]-n,n,n-trimethyl-,innersalt,rel- |
Role | Description |
---|---|
mouse metabolite | Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus). |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
sphingomyelin 36:1 | A sphingomyelin in which the total number of carbons in the sphingoid base and fatty acyl groups is 36 with 1 double bond. |
sphingomyelin d18:1 | Any sphingomyelin having sphingosine as the sphingoid component. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Pathway | Proteins | Compounds |
---|---|---|
Sphingolipid metabolism (integrated pathway) | 11 | 67 |
Sphingolipid metabolism: integrated pathway | 1 | 63 |
Sphingolipid pathway | 3 | 15 |
Sphingolipids metabolism pathway | 0 | 63 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 44.6684 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (30.00) | 18.7374 |
1990's | 3 (30.00) | 18.2507 |
2000's | 2 (20.00) | 29.6817 |
2010's | 2 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.96) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 11 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |